UroGen Pharma (FRA:UR8) LT-Debt-to-Total-Asset: 0.77 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UR8 UroGen Pharma Ltd FRA:UR8
60 GF Score
Price €33.52
GF Value €17.71
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is UroGen Pharma LT-Debt-to-Total-Asset?

UroGen Pharma FRA:UR8 -1.00% 60 LT-Debt-to-Total-Asset is 0.77 as of Mar. 2026. GuruFocus rates FRA:UR8 with a GF Score™ of 60/100 and a GF Value™ of €17.71 (Significantly Overvalued). The stock has 10 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. UroGen Pharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.77.

UroGen Pharma's long-term debt to total assets ratio increased from Mar. 2025 (0.51) to Mar. 2026 (0.77). It may suggest that UroGen Pharma is progressively becoming more dependent on debt to grow their business.

UroGen Pharma  (FRA:UR8) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

UroGen Pharma LT-Debt-to-Total-Asset Related Terms

UroGen Pharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for UroGen Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma LT-Debt-to-Total-Asset Chart

UroGen Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.73 0.56 0.43 0.64

UroGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.60 0.69 0.64 0.77
FRA:UR8
60GF Score
UroGen Pharma Ltd FRA:UR8
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UroGen Pharma LT-Debt-to-Total-Asset Calculation

UroGen Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=109.596/171.189
=0.64

UroGen Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=168.828/219.442
=0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.77 mean?
UroGen Pharma (FRA:UR8) has a LT-Debt-to-Total-Asset of 0.77 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on UroGen Pharma and its competitors.
Is UroGen Pharma's LT-Debt-to-Total-Asset too high?
UroGen Pharma's current LT-Debt-to-Total-Asset is 0.77. Overall, UroGen Pharma has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's LT-Debt-to-Total-Asset compare to SEPN and FTRE?
UroGen Pharma's LT-Debt-to-Total-Asset of 0.77 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current LT-Debt-to-Total-Asset is 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.71, compared to a current price of €33.52 — trading 89.3% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.77. UroGen Pharma's overall GF Score™ is 60/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current LT-Debt-to-Total-Asset is 0.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (FRA:UR8) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of €33.52 is trading 89.3% above its estimated GF Value™ of €17.71. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for FRA:UR8:

  • LT-Debt-to-Total-Asset: 0.77
  • GF Value™: €17.71 vs. price of €33.52 (89.3% above fair value)
  • GF Score™: 60/100 with 10 warning signs

No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UroGen Pharma Business Description

Other Exchanges URGN:USA0XOD:UK
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
60GF Score

Get the complete analysis for FRA:UR8

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.52
Price
€17.71
GF Value